metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mGC or mGEJC - L1 - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 neg/PDL1 positive
mGC or mGEJC - L1 - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 negative
mGC or mGEJC - L1 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - PDL1 positive
mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population
versus paclitaxel
	avelumab alone vs. paclitaxel	1	1.10 [0.88; 1.37], 1 RCT, I2=0% inconclusive result	1.73 [1.38; 2.17], 1 RCT, I2=0% statistically significant harm	-
mGC or mGEJC - L2 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - PDL1 positive
mGC or mGEJC - M - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 negative
versus Standard of Care (SoC)
	avelumab alone vs. Standard of Care (SoC)	1	0.91 [0.74; 1.11], 1 RCT, I2=0% inconclusive result	1.04 [0.85; 1.28], 1 RCT, I2=0% inconclusive result	-
mGC or mGEJC - M - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 neg/PDL1 positive
versus Standard of Care (SoC)
	avelumab alone vs. Standard of Care (SoC)	1	1.13 [0.57; 2.24], 1 RCT, I2=0% inconclusive result	1.04 [0.53; 2.03], 1 RCT, I2=0% inconclusive result	-